Atossa Therapeutics announced that each share of its common stock will now trade with one attached contingent value right (CVR), linked to potential proceeds from a future priority review voucher (PRV) if awarded by the FDA. The CVRs remain stapled to shares and transfer together, entitling holders to 25% of net proceeds from the first qualifying PRV, capped at $50 million. This structure aligns shareholder interests with potential PRV value while allowing Atossa to maintain strategic flexibility. No PRV has yet been awarded, and the CVRs apply to PRVs received by December 31, 2036, subject to board extension.
Atossa Therapeutics Common Stock trading with stapled contingent value rights is the subject here. For readers following the Health sector, here is Pluang's market snapshot as of Oct 19, 2026 18:43 WIB: out of 150 priced Health-sector US stocks, 68 rose and 54 fell. Notable movers include IOVA at USD 13.80 with a 1-day change of +1.32% and a typical hold time of 2 days, SANA at USD 2.30 with a +1.32% change and 24 days hold time, and SNY at USD 40.09 with a -1.28% change and 94 days hold time.
Bill Gross, a serial entrepreneur behind over 175 companies, has launched Idealab.ai, a platform using AI to generate and share over 1.2 million business ideas based on real-world problems. The platform aims to lower barriers to entrepreneurship by h...
The Portnoy Law Firm has launched an investigation into Cardinal Infrastructure Group for possible securities fraud following the company's Q2 2026 financial report. Cardinal revealed a decline in its gross profit margin to 10.8%, down from 13.9% the...
AIOS Tech Inc. announced an agreement to acquire SmartCore Holdings Limited in an all-stock transaction valued at approximately $100 million. The deal will issue 33.3 million AIOS shares to SmartCore's sellers, who will hold about 80% of AIOS shares ...
XBiotech announced positive results from the Phase II TASKIN trial, where their antibody vilamakitug combined with standard chemotherapy improved 12-month overall survival to 61.3% in refractory metastatic colorectal cancer patients, surpassing the s...
Proof and Circle Internet Group demonstrated a new system where AI agents can prove the identity of the person they represent using Proof's x401 open identity protocol and pay merchants in USDC via Circle's x402 payment protocol. This innovation addr...
